ORGANIZATION

• JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
  April 15, 2026

• Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
  April 8, 2026

• Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
  April 8, 2026

• Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
  April 7, 2026

• Generic Use Rate Hits 90% for First Time in October-December: JGA
  April 7, 2026

• JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
  April 2, 2026

• Five Groups Urge Action to Secure Medical Supplies amid Iran War
  April 2, 2026

• JPMA Unveils Committee Action Plans, Prioritizes Innovation-Focused Drug Pricing
  April 2, 2026

• UCB’s Kikuchi Appointed EFPIA Japan Vice Chair
  April 2, 2026

• JMA’s Ezawa Calls for “National Debate” on Drug Policy
  March 31, 2026

• BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
  March 25, 2026

• Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
  March 24, 2026

• FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
  March 24, 2026

• FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
  March 23, 2026

• JPMA Names Shionogi’s Go Takahashi as Managing Director
  March 23, 2026

• JPMA Seeks Japan Version of EHDS to Unlock Life-Course Health Data
  March 23, 2026

• EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
  March 2, 2026

• Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
  February 24, 2026

• JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
  February 20, 2026

• Pharma Group Looks to Growth Strategy under Takaichi after Election Win
  February 10, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »